Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP

• Status: Recruiting
• Trial end date: 2022-07-08
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, randomized clinical trial. During the study, non-HIV patients who are admitted to ICU due to Pneumocystic pneumonia (PCP) and have not received anti-PCP therapy or have received therapy less than 48hrs will be randomized (1:1) to received caspofungin combined with trimethoprim-sulfamethoxazole or trimethoprim-sulfamethoxazole alone.

The aim of this study is to compare the effectiveness of caspofungin combined with trimethoprim-sulfamethoxazole with that of conventional therapy (trimethoprim-sulfamethoxazole alone) as first-line therapy in the treatment of severe Pneumocystis pneumonia (PCP) in non-HIV patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bin Du
• Treatments: Caspofungin; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Sulfamethoxazole; Sulfisoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

Criteria

Inclusion Criteria:

1. Age ≥ 18 years old

2. Non-HIV immunosuppressed patients admitted to the ICU

3. confirmed or suspect PCP

3) Not receiving anti-PCP treatment or anti-PCP treatment < 48 hours

Exclusion Criteria:

1. Age less than 18 years old

2. Known pregnancy

3. allergy to TMP/SMZ or caspofungin

4. Decision to withhold life-sustaining treatment

5. Patients with advanced pulmonary fibrosis

6. severe liver dysfunction(Child-Pugh C )